Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co. Inc. daily Stock Chart
MRK [NYSE]
Merck & Co. Inc.
IndexDJIA S&P500 P/E35.88 EPS (ttm)1.64 Insider Own0.04% Shs Outstand2.77B Perf Week-0.27%
Market Cap162.72B Forward P/E15.65 EPS next Y3.75 Insider Trans-22.65% Shs Float2.77B Perf Month2.82%
Income4.62B PEG7.04 EPS next Q0.91 Inst Own74.90% Short Float1.10% Perf Quarter7.84%
Sales39.39B P/S4.13 EPS this Y-61.60% Inst Trans0.05% Short Ratio3.44 Perf Half Y17.73%
Book/sh15.79 P/B3.72 EPS next Y0.81% ROA4.60% Target Price61.85 Perf Year3.71%
Cash/sh4.67 P/C12.57 EPS next 5Y5.10% ROE10.20% 52W Range44.16 - 59.95 Perf YTD12.94%
Dividend1.84 P/FCF27.96 EPS past 5Y41.50% ROI6.40% 52W High-2.15% Beta0.66
Dividend %3.14% Quick Ratio1.30 Sales past 5Y-3.00% Gross Margin62.80% 52W Low32.83% ATR0.76
Employees68000 Current Ratio1.60 Sales Q/Q-1.20% Oper. Margin18.20% RSI (14)55.21 Volatility1.30% 1.16%
OptionableYes Debt/Eq0.59 EPS Q/Q20.60% Profit Margin11.70% Rel Volume0.96 Prev Close58.43
ShortableYes LT Debt/Eq0.54 EarningsJul 29 BMO Payout110.40% Avg Volume8.81M Price58.66
Recom2.50 SMA20-0.29% SMA502.63% SMA20010.06% Volume8,488,443 Change0.39%
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Jul-29-16 11:06PM  [$$] Earnings Watch at The Wall Street Journal
04:57PM  Merck posts strong 2Q numbers, while building for long term
04:38PM  AbbVie, Merck Beat Earnings Estimates, But Sanofi Lags
01:53PM  Merck Second-Quarter Results Beat Forecasts at TheStreet
01:17PM  [$$] Merck Revenue Rises on Cancer, Hepatitis Treatments at The Wall Street Journal
01:10PM  Merck Needs Stronger Top-Line Medicine at Bloomberg
12:56PM  S&P 500 touches record intraday high; Dow hamstrung by Exxon shares at MarketWatch
12:28PM  Investors Should Be Protective of Merck Gains
11:36AM  Buy Merck on Near-Term Weakness
11:29AM  Stocks Mixed: Mighty Amazon Vs. Weak GDP, Oil
10:14AM  Edited Transcript of MRK earnings conference call or presentation 29-Jul-16 12:00pm GMT
10:14AM  Merck (MRK) Updates Outlook Following Q2 Earnings Beat
10:07AM  Trending Stocks: Xerox, LyondellBasell, Enbridge, and 2 More at Insider Monkey
09:15AM  Merck quarterly results beat forecasts, shares rise
08:40AM  5 Things You Must Know Before the Market Opens Friday
08:20AM  Merck Raises EPS Outlook After Q2 Earnings at 24/7 Wall St.
08:18AM  Merck (MRK) Beats on Q2 Earnings by a Penny
08:13AM  Stocks to Watch: July 29, 2016
07:45AM  Investors Greet Merck Q2 Results As Key Launches Help Beat
07:34AM  Merck Shares Rise After Second-Quarter Earnings Top Forecasts
07:15AM  Beyond Merck's yield is value: Pro
07:07AM  Q2 2016 Merck & Co Inc Earnings Release - Before Market Open
07:00AM  European Commission Grants Marketing Authorisation for MSDs ZEPATIER (elbasvir/grazoprevir) for the Treatment of Chronic Hepatitis C Infection Business Wire
06:59AM  Merck's profit and revenue rise above expectations at MarketWatch
06:59AM  MERCK & CO., INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
06:54AM  Merck & Co reports 1 pct rise in quarterly revenue
06:46AM  Merck Profit Beats Analysts Estimates on Diabetes Drug Sales at Bloomberg
06:45AM  Merck Announces Second-Quarter 2016 Financial Results Business Wire
Jul-28-16 11:55AM  Merck (MRK) Stock Down Ahead of Q2 Earnings
11:05AM  Mercks 2Q16 Estimates: Products with Declining Sales
09:07AM  Mercks 2Q16 Estimates: Expected Growth Contributors
06:47AM  2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
02:46AM  Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China CNW Group
Jul-27-16 05:16PM  A Powerful New Antibiotic May Have Been Living in Our Noses This Whole Time at Fortune
11:22AM  Can Keytruda Deliver Earnings Growth For Merck?
09:12AM  Why Investors Can Expect Operational Growth from Merck in 2Q16
09:08AM  Will Bristol-Myers Squibb See Higher Sales for Eliquis in 2Q16?
08:25AM  Short Sellers Get Selective on Major Pharma at 24/7 Wall St.
06:47AM  What to Expect from Mercks 2Q16 Earnings
01:27AM  [$$] From Farm to Pharma, Former CEO Recalls First Job as Laborer at The Wall Street Journal
Jul-26-16 03:34PM  Harvoni Sales Declines Hurt Gilead Sciences Inc. in Q2 at Motley Fool
02:09PM  FDA enhances warnings on group of strong antibiotics Reuters
12:50PM  Merck Announces Fourth-Quarter 2016 Dividend Business Wire
12:34PM  [$$] Former CEO Recalls First Job as Farm Laborer at The Wall Street Journal
09:05AM  A Look at Roches Potential Revenue Drivers
07:24AM  Merck (MRK) Q2 Earnings: Will the Stock Pull a Surprise?
Jul-25-16 11:15AM  Gilead Sciences Kicks Off 5 Big Pharma Earnings This Week
11:09AM  Germany plans to extend price brake for drugs under statutory insurance Reuters
11:04AM  Eli Lillys Valuation Cheat Sheet for 2Q16
10:47AM  Merck (MRK) Stock Down, Ebola Vaccine Under 'Accelerated' FDA Review
09:18AM  Merck Gets Breakthrough Therapy Status From FDA And PRIME Status From EMA For Investigational Ebola Zaire Vaccine
09:07AM  Sales Performance Analysis of Roches Pharmaceuticals Division
08:05AM  NewLink Genetics Announces Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920) GlobeNewswire
08:00AM  Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920) Business Wire
05:47AM  The Economy, Interest Rates, Earnings and the Markets
Jul-24-16 07:59AM  The Economy, Interest Rates, Earnings and the Markets
Jul-23-16 11:41AM  In Case You Missed It, 5 New Lung Cancer Drugs Have Been Approved Since October at Motley Fool
Jul-22-16 04:11PM  Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other
12:08PM  Merck Presents Data On Its Investigational Once-Daily Formulation Of ISENTRESS
12:07PM  Market Exclusives Inside the FDA: This Week Bezlotoxumab from Merck & Co., Inc. (MRK) at Insider Monkey
07:00AM  Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation... Business Wire
Jul-21-16 05:24PM  More Than 400 Women Are Now Suing Merck for Unequal Pay at Fortune
05:00PM  Merck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner topical solution) for Cats and Dogs Business Wire
04:30PM  Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab Business Wire
04:20PM  Sorry, You Can't Buy This Hot Biotech -- At Least Not Directly at Motley Fool
01:49PM  How Did Novartiss 2Q16 Earnings Stand up to Analyst Estimates?
12:10PM  These 5 Big Stocks Are Breaking Out This Summer
09:03AM  These 5 Healthcare Stocks Have Huge Dividend Yields -- Are Any Worth Buying? at Motley Fool
Jul-20-16 03:00PM  Six Major Biotech Acquisitions You Could See In 2016 (Part 1) at Forbes
11:17AM  U.S. healthcare stock bulls look past political risks
07:47AM  What's behind heavy put volume in Merck
Jul-19-16 01:15PM  Merck & Co., Inc. (MRK) and OpGen Inc (OPGN) Are Quietly Changing The Infectious Disease Landscape at Insider Monkey
12:00PM  Why a Trump Win Could Be Good News for Pfizer, IBM at Barrons.com
09:23AM  Merck KGaA's Multiple Sclerosis Drug under Review in EU
08:22AM  5 Big Pharma Stocks Struggling to Raise Their Dividends at Motley Fool
07:20AM  Cambridges Jounce announces hefty $2.5B deal with Celgene for cancer drugs at bizjournals.com
Jul-18-16 02:58PM  Here's When You Should Buy Merck
11:06AM  Analyst: Merck's Fundamentals Don't Warrant Current Valuation
09:41AM  Merck (MRK) Stock Slides, BMO Downgrades
09:08AM  Ligand Pharmaceuticalss Portfolio Pyramid as Its Valuation Catalyst
08:15AM  Analysts' Actions -- Groupon, Humana, Monster, Merck and More
Jul-17-16 05:54AM  Herd Mentality
Jul-15-16 05:29PM  Two of the Worlds Best-Selling Drugs Are Headed for a Lot More Competition at Fortune
01:08PM  5 Overvalued Dow Components
10:36AM  Gilead's HCV Drug Epclusa Gets Regulatory Nod in Canada
09:27AM  Is Advaxis' Stock Now a Bargain? at Motley Fool
Jul-14-16 07:01PM  UK charity pockets $150 mln from Merck cancer immunotherapy drug
03:10PM  Here's where Merck's new Cambridge research facility will be located at bizjournals.com
Jul-13-16 03:22PM  Merck to Axe Jobs As Part of New Research Focus at Fortune
09:15AM  Short Sellers Run for Cover From Major Pharma at 24/7 Wall St.
07:30AM  Merck to open new Cambridge facility for microbiome research this year at bizjournals.com
06:35AM  Big Pharma eyes Bay Area, Boston expansions as it cuts R&D elsewhere at bizjournals.com
Jul-12-16 05:06PM  These Four Drugs Were Withdrawn by the CHMP in June
05:06PM  The CHMP Just Recommended the Extension of These Drugs Therapeutic Indications
02:59PM  Merck (MRK) Stock Gaining, Cutting Research Jobs
02:52PM  [$$] Merck to Cut Research Jobs at Three East-Coast Sites at The Wall Street Journal
02:44PM  Why Relypsa Stock Is Ripping
10:07AM  Rova-T and Immuno-Oncology Therapies May Be Complementary
Jul-11-16 03:13PM  Why AbbVies Rova-T May Have More Growth Potential than Predicted
09:07AM  Is It Slower Growth for Regenerons Eylea in 2016 and 2017?
Merck & Co., Inc. provides health care solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also provides neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for the treatment of C. difficile, and vaccines against bacterial and viral disease in fish. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEOJul 05Option Exercise51.0227,6211,409,223550,098Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Sale58.0027,6211,602,018522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 05Sale57.9945,0002,609,33087,151Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Option Exercise40.7030,0001,221,000162,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Option Exercise44.3050,0002,215,00050,000Jul 01 01:13 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Option Exercise51.0232,3791,651,977554,856Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Sale58.0032,3791,877,982522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Sale57.4930,0001,724,553132,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Sale57.6950,0002,884,4150Jul 01 01:13 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Option Exercise44.9838,6471,738,34255,730May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Sale54.8038,6472,117,85617,083May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 19Sale54.551,23067,09717,083May 20 02:34 PM
Holston Michael JEVP, General CounselMay 10Option Exercise44.58100,0214,458,989164,301May 12 11:39 AM
Holston Michael JEVP, General CounselMay 10Sale54.50100,0215,451,14564,280May 12 11:39 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 06Option Exercise0.003,335025,928May 09 04:21 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 06Option Exercise0.004,002040,221May 09 04:21 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 06Option Exercise0.002,001015,375May 09 04:21 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLMay 06Option Exercise0.0044,464094,899May 09 04:21 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 06Option Exercise0.004,002033,430May 09 04:20 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM
WEEKS WENDELL PDirectorNov 04Option Exercise34.445,000172,2005,100Nov 04 04:37 PM
WEEKS WENDELL PDirectorNov 04Sale55.535,000277,669100Nov 04 04:37 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Option Exercise35.0918,666654,990456,902Oct 30 04:58 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Option Exercise36.5637,3131,364,16357,008Oct 29 04:23 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Sale55.0837,3132,055,33419,695Oct 29 04:23 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Sale54.6918,6661,020,758438,236Oct 30 04:58 PM
WENDELL PETER CDirectorOct 28Option Exercise34.445,000172,2006,000Oct 28 02:44 PM
WENDELL PETER CDirectorOct 28Sale54.855,000274,2371,000Oct 28 02:44 PM
Holston Michael JEVP, General CounselAug 01Option Exercise0.0022,584062,584Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Option Exercise39.8335,5421,415,54643,994Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Sale59.0931,8311,880,80512,163Aug 04 02:41 PM